Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jul;57(7):746-51.
doi: 10.1136/jcp.2003.014480.

Lack of lymphangiogenesis during breast carcinogenesis

Affiliations

Lack of lymphangiogenesis during breast carcinogenesis

M M Vleugel et al. J Clin Pathol. 2004 Jul.

Abstract

Background: Recent evidence suggests that functional intratumorous lymph vessels may be absent from some human cancers. This could result from either the failure of tumours to induce lymphangiogenesis, or the collapse of lymph vessels, caused by high interstitial tumour pressure.

Methods: To differentiate between these two hypotheses, paraffin wax embedded clinical specimens from normal breast (n = 13), usual ductal hyperplasia (n = 11), ductal carcinoma in situ (n = 21), and invasive breast cancer (n = 40) were compared for lymphatic and blood vessel density by immunohistochemistry with antibodies to the lymphatic endothelial hyaluronan receptor (LYVE-1) and CD31, respectively.

Results: Lymph vessel density was lower than blood vessel density in normal breast tissue. Within breast lobuli, lymph vessels were absent. In premalignant lesions blood microvessel density increased, whereas no increase in lymph vessels could be seen intralesionally. In invasive cancers, lymph vessels were absent in all but a few cases, where probably some pre-existing lymph vessels remained, although blood microvessel density was once again increased.

Conclusion: Unlike angiogenesis, lymphangiogenesis is absent during breast carcinogenesis. This, and not rising interstitial pressure caused by an increase in the size of lesions, explains the absence of intratumorous lymph vessels in invasive breast cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Lymph and blood vessel patterns in the normal human breast, premalignant lesions, and invasive breast cancer. (A) In the normal breast, scattered lymph vessels are seen in the interlobular stroma. No intralobular lymph vessels are seen. Arrow: unstained blood vessel associated with lymph vessels. (B) In the normal breast, numerous blood vessels are seen, also in the intralobular space. (C) Lymph vessels are present at some distance in the adipose tissue surrounding usual ductal hyperplasia. (D) Ductal carcinoma in situ with lymph vessels in the surrounding stroma at some distance from the neoplastic ducts. (E) Blood vessels are present as a vascular rim around a ductal carcinoma in situ. (F) In invasive breast cancer, lymphatics are seen at the tumour margin, but are absent from the intratumorous stroma in most cases. (G) In invasive breast cancer, intratumorous lymphatics are seen occasionally in the intratumorous stroma in some cases. (H) In invasive breast cancer, intratumorous blood vessels are dispersed within the tumour.

Comment in

References

    1. Karpanen T , Egeblad M, Karkkainen MJ, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001;61:1786–90. - PubMed
    1. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A 1998;95:548–53. - PMC - PubMed
    1. Kaipainen A , Korhonen J, Mustonen T, et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 1995;92:3566–70. - PMC - PubMed
    1. Valtola R , Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999;154:1381–90. - PMC - PubMed
    1. Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 1999;86:2406–12. - PubMed

Publication types

MeSH terms